Loading…
Olema Pharmaceuticals, Inc. is projected to decline to $11.64 by 2027, a -2% move from its current price of $11.92. OLMA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $11.54 | $11.93 | $12.33 | +0.08% |
| Jul 14 | $11.39 | $11.94 | $12.51 | +0.15% |
| Jul 15 | $11.28 | $11.95 | $12.65 | +0.23% |
| Jul 16 | $11.19 | $11.96 | $12.77 | +0.30% |
| Jul 17 | $11.11 | $11.97 | $12.88 | +0.38% |
| Jul 18 | $11.05 | $11.97 | $12.98 | +0.46% |
| Jul 19 | $10.98 | $11.98 | $13.08 | +0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.98 | $11.98 | $13.08 | +0.53% |
| Week 2 | $10.65 | $12.05 | $13.63 | +1.07% |
| Week 3 | $10.41 | $12.11 | $14.09 | +1.61% |
| Week 4 | $10.23 | $12.18 | $14.50 | +2.15% |
| Week 5 | $10.07 | $12.24 | $14.88 | +2.69% |
| Week 6 | $9.94 | $12.31 | $15.24 | +3.24% |
| Week 7 | $9.82 | $12.37 | $15.58 | +3.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate palazestrant is an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers.
The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals, Inc. (OLMA) trades in the healthcare sector with a current price of $12.51 and a market capitalization of $1.09B. Its market rank is 2486. The outlook for Olema is shaped by a year-by-year forecast extending through 2050, which depicts a near-term neutral path and a long-term bullish trajectory as price levels and ROIs rise in the later years.
A major floor 37.7% below — a decisive break under it would weaken the trend.
The nearest floor, 22.9% below — buyers have tended to step in here.
The nearest ceiling, 10.7% above — a clean break opens room to run.
A major ceiling 104.2% above — clearing it would confirm fresh momentum.
Key OLMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OLMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.37 | Sell | $12.20 | Sell |
| MA 10 | $12.27 | Sell | $12.04 | Sell |
| MA 20 | $11.17 | Buy | $11.77 | Buy |
| MA 50 | $12.32 | Sell | $12.60 | Sell |
| MA 100 | $14.98 | Sell | $14.35 | Sell |
| MA 200 | $17.34 | Sell | $14.77 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.95 | Neutral |
| Stoch RSI (14) | 60.59 | Neutral |
| CCI (20) | 43.87 | Neutral |
| Williams %R (14) | -31.05 | Info |
| MACD (12,26,9) | 0.23 | Buy |
| ROC (12) | 13.11 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 68.95 | Neutral |
| TRIX (15) | -0.13 | Sell |
| Awesome (5,34) | 0.94 | Buy |
| Ultimate (7,14,28) | 47.35 | Neutral |
| Momentum (10) | 0.48 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 12.23 | Sell |
| ADX (14) | 21.34 | Buy |
| ATR (14) | 0.35 | Info |
The 30-day technical picture is NEUTRAL, with the RSI (14) at 60, indicating balanced momentum. The 50-day simple moving average sits at $12.79, while the 200-day simple moving average is $17.19. Key support is at $9.19 and resistance at $14.06, framing a near-term trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.19 | $11.92 | $16.03 | 0% | Neutral | |
| $9.09 | $11.64 | $15.88 | -2% | Neutral | |
| $8.73 | $11.57 | $16.48 | -3% | Neutral | |
| $9.31 | $12.70 | $18.72 | +7% | Neutral | |
| $8.68 | $12.15 | $18.42 | +2% | Neutral | |
| $10.28 | $14.73 | $22.87 | +24% | Bullish | |
| $11.84 | $17.34 | $27.54 | +46% | Bullish | |
| $11.07 | $16.55 | $26.81 | +39% | Bullish | |
| $11.09 | $16.90 | $27.88 | +42% | Bullish | |
| $10.70 | $16.63 | $27.89 | +40% | Bullish | |
| $14.60 | $24.73 | $44.50 | +107% | Bullish | |
| $20.14 | $39.79 | $79.24 | +234% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.19 | $11.92 | $14.51 | +0.00% |
| August 2026 | $10.69 | $12.69 | $15.52 | +6.42% |
| September 2026 | $10.67 | $12.77 | $15.83 | +0.70% |
| October 2026 | $10.29 | $12.41 | $15.56 | -2.84% |
| November 2026 | $10.26 | $12.45 | $15.75 | +0.33% |
| December 2026 | $10.30 | $12.57 | $16.03 | +0.92% |
Click any year to see its month-by-month OLMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect OLMA to range from $9.19 to $16.03 through 2026. The $11.92 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The OLMA price prediction for 2027 points to an average of $11.64 (low $9.09, high $15.88) — a potential decline of -2% on today's $11.92. A consolidation phase looks the most probable path here.
In 2028, OLMA is projected to trade between $8.73 and $16.48, averaging $11.57 — a potential decline of -3% from today's $11.92. That is -1% versus the projected 2027 average. Price action looks broadly range-bound.
Olema Pharmaceuticals, Inc.'s 2029 outlook centres on $12.70, within a $9.31 to $18.72 range. That is up +10% on the projected 2028 average. That marks a +7% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, OLMA could reach as high as $18.42, with a base case around $12.15 and support toward $8.68 — roughly +2% from $11.92. Price action looks broadly range-bound.
Expect OLMA to range from $10.28 to $22.87 through 2031. The $14.73 average target implies a +24% move from current prices. That is up +21% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The OLMA price prediction for 2032 points to an average of $17.34 (low $11.84, high $27.54) — a potential gain of +46% on today's $11.92. Momentum favours further upside here.
In 2033, OLMA is projected to trade between $11.07 and $26.81, averaging $16.55 — a potential gain of +39% from today's $11.92. That is -5% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Olema Pharmaceuticals, Inc.'s 2034 outlook centres on $16.90, within a $11.09 to $27.88 range. That is up +2% on the projected 2033 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2035, OLMA could reach as high as $27.89, with a base case around $16.63 and support toward $10.70 — roughly +40% from $11.92. Buyers look set to stay in control over this stretch.
Expect OLMA to range from $14.60 to $44.50 through 2040. The $24.73 average target implies a +107% move from current prices. That is up +49% on the projected 2035 average. Momentum favours further upside here.
The OLMA price prediction for 2050 points to an average of $39.79 (low $20.14, high $79.24) — a potential gain of +234% on today's $11.92. Buyers look set to stay in control over this stretch.
Investing $1,000 in OLMA today (≈ 83.892617 OLMA) could be worth
$3,338.15
+$2,338.15 (+234%) by 2050 · US Dollar
Based on the average projected OLMA price of $39.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OLMAwould be worth at today's price.
$1,000 invested in OLMA on Jul 10, 2025 (≈ 206.185571 OLMA) would be worth
$2,457.73
+$1,457.73 (+145.8%) today · 2.46× · US Dollar
Based on a OLMA entry price of $4.85 vs. today's $11.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.64 | $943.04 | -5.7% |
| 1 month ago | $9.82 | $1,213.85 | +21.4% |
| 3 months ago | $16.1 | $740.37 | -26.0% |
| 6 months ago | $28.79 | $414.03 | -58.6% |
| 1 year ago | $4.85 | $2,457.73 | +145.8% |
| All time (5.0y) ago | $25.64 | $464.9 | -53.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OLMA forecast.
Our base-case forecast reaches $24.00 around 2040.
Implied market cap at $24.00: $2.1B
The multi-year forecast shows a mixed near-term path and a stronger longer-term upside. For 2026 the average forecast price is $12.51 with a range of $9.19 to $17.03 and a 0% ROI, sentiment NEUTRAL. The 2027 and 2028 perspectives remain NEUTRAL with averages of $12.07 and $12.20 and ROIs of -3.5% and -2.5%, respectively.
Tap a question to reveal the answer.
The 2030 forecast shows an average of $12.62 with a min of $8.74, a max of $19.78, and a 0.9% ROI; sentiment is NEUTRAL.
Near-term sentiment is NEUTRAL with modest expected moves. Longer-term, the outlook turns BULLISH for 2031 and beyond, with ROIs of 28.4% in 2031, 50.8% in 2032, 40.1% in 2033, 45.3% in 2034, and 41% in 2035, culminating in substantial potential upside through 2050.
Yes. The forecast shows a max of $31.10 in 2032 and $31.23 in 2034, with subsequent years like 2035 at $30.88 is also possible within the projected range.
The 2040 forecast has an average of $27.37 with a min of $15.08, a max of $51.72, and a RO I of 118.8%; sentiment is BULLISH.
For 2050 the average is $42.89 with a min of $19.52, a max of $90.43, and a RO I of 242.8%; sentiment is BULLISH.
Olema Pharmaceuticals, Inc. Community Discussion
0Share your Olema Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.